- Stocks
- Healthcare
- NASDAQ: BEAM

Price (delayed)

$24.4

Market cap

$2.01B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.63

Enterprise value

$1.88B

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a

The EPS has surged by 64% year-on-year

The debt has contracted by 7% YoY

The net income has surged by 56% year-on-year but it has declined by 6% since the previous quarter

BEAM's quick ratio is up by 10% year-on-year but it is down by 2.7% since the previous quarter

BEAM's gross profit is down by 2.3% since the previous quarter

Beam Therapeutics's revenue has decreased by 2.3% from the previous quarter

What are the main financial stats of BEAM

Market
Valuations
Earnings

Shares outstanding

82.42M

Market cap

$2.01B

Enterprise value

$1.88B

Price to earnings (P/E)

N/A

Price to book (P/B)

2.35

Price to sales (P/S)

5.7

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

5.32

Revenue

$352.57M

EBIT

-$141.61M

EBITDA

-$120.05M

Free cash flow

-$153.4M

Per share
Balance sheet
Liquidity

EPS

-$1.63

Free cash flow per share

-$1.86

Book value per share

$10.38

Revenue per share

$4.28

TBVPS

$15.32

Total assets

$1.26B

Total liabilities

$407.17M

Debt

$165.24M

Equity

$854.09M

Working capital

$852.11M

Debt to equity

0.19

Current ratio

5.81

Quick ratio

5.72

Net debt/EBITDA

1.11

Margins
Efficiency
Dividend

EBITDA margin

-34.1%

Gross margin

100%

Net margin

-40.6%

Operating margin

-52.3%

Return on assets

-10.6%

Return on equity

-16.2%

Return on invested capital

-14%

Return on capital employed

-13.1%

Return on sales

-40.2%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Beam Therapeutics stock price performed over time

Intraday

1.16%

1 week

0.91%

1 month

1.75%

1 year

-6.8%

YTD

-10.36%

QTD

4.14%

How have Beam Therapeutics's revenue and profit performed over time

Revenue

$352.57M

Gross profit

$352.57M

Operating income

-$184.44M

Net income

-$143.01M

Gross margin

100%

Net margin

-40.6%

The net margin has soared by 90% YoY but it has contracted by 9% from the previous quarter

Beam Therapeutics's operating margin has surged by 89% YoY but it has decreased by 4% QoQ

The net income has surged by 56% year-on-year but it has declined by 6% since the previous quarter

Beam Therapeutics's operating income has surged by 52% YoY

What is Beam Therapeutics's growth rate over time

What is Beam Therapeutics stock price valuation

P/E

N/A

P/B

2.35

P/S

5.7

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

5.32

The EPS has surged by 64% year-on-year

The price to book (P/B) is 61% lower than the 5-year quarterly average of 6.0 and 7% lower than the last 4 quarters average of 2.5

BEAM's equity is down by 7% since the previous quarter but it is up by 5% year-on-year

BEAM's price to sales (P/S) is 100% lower than its 5-year quarterly average of 46292.8 and 46% lower than its last 4 quarters average of 10.5

Beam Therapeutics's revenue has decreased by 2.3% from the previous quarter

How efficient is Beam Therapeutics business performance

The return on sales has surged by 90% year-on-year but it has declined by 9% since the previous quarter

The ROE has soared by 63% YoY but it has decreased by 4.5% QoQ

The company's return on assets has surged by 56% YoY but it fell by 7% QoQ

BEAM's ROIC has soared by 54% YoY but it is down by 9% QoQ

What is BEAM's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BEAM.

How did Beam Therapeutics financials performed over time

Beam Therapeutics's total liabilities has decreased by 25% YoY and by 9% QoQ

BEAM's current ratio is up by 11% YoY but it is down by 3% QoQ

The debt is 81% less than the equity

The company's debt to equity fell by 14% YoY but it rose by 6% QoQ

BEAM's equity is down by 7% since the previous quarter but it is up by 5% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.